Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer

被引:15
|
作者
Liu, Xiaoran [1 ]
Ran, Ran [1 ]
Shao, Bin [1 ]
Rugo, Hope S. [2 ]
Yang, Yanlian [3 ]
Hu, Zhiyuan [3 ]
Wei, Zewen [3 ]
Wan, Fengling [1 ]
Kong, Weiyao [1 ]
Song, Guohong [1 ]
Jiang, Hanfang [1 ]
Liang, Xu [1 ]
Zhang, Ruyan [1 ]
Yan, Ying [1 ]
Xu, Guobing [4 ]
Li, Huiping [1 ]
机构
[1] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Breast Oncol,Canc Hosp & Inst, Beijing 100142, Peoples R China
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA
[3] Chinese Acad Sci, Key Lab Standardizat & Measurement Nanotechnol, Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China
[4] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Clin Lab,Canc Hosp & Inst, Beijing 100142, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; nanotechnology; circulating tumor cell; immunology; MOLECULAR SUBTYPES; DENDRITIC CELLS; IMMUNE-SYSTEM; NK-CELLS; T-CELLS; EXPRESSION; BLOOD; PHENOTYPE;
D O I
10.21147/j.issn.1000-9604.2018.03.04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. Methods: In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. Results: Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). Conclusions: Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.
引用
收藏
页码:315 / +
页数:15
相关论文
共 50 条
  • [1] Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer
    Xiaoran Liu
    Ran Ran
    Bin Shao
    Hope S.Rugo
    Yanlian Yang
    Zhiyuan Hu
    Zewen Wei
    Fengling Wan
    Weiyao Kong
    Guohong Song
    Hanfang Jiang
    Xu Liang
    Ruyan Zhang
    Ying Yan
    Guobing Xu
    Huiping Li
    Chinese Journal of Cancer Research, 2018, 30 (03) : 315 - 326
  • [2] Combined peripheral natural killer (NK) cell and circulating tumor cell (CTC) enumeration to enhance prognostic efficiency in patients (pts) with triple negative breast cancer (TNBC)
    Liu, Xiao-ran
    Shao, Bin
    Li, Hui-ping
    Yang, Yan-lian
    Rugo, Hope S.
    Kong, Wei-yao
    Song, Guo-hong
    Jiang, Han-fang
    Liang, Xu
    Yan, Ying
    Hu, Zhi-yuan
    Xu, Guo-bing
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
    Magbanua, Mark Jesus M.
    Carey, Lisa A.
    DeLuca, Amy
    Hwang, Jimmy
    Scott, Janet H.
    Rimawi, Mothaffar F.
    Mayer, Erica L.
    Marcom, P. Kelly
    Liu, Minetta C.
    Esteva, Francisco J.
    Park, John W.
    Rugo, Hope S.
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1098 - 1105
  • [4] Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer
    Zivanovic Bujak, Andjelija
    Dawson, Sarah-Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06) : 523 - 524
  • [5] Monitoring of circulating tumor DNA in metastatic triple-negative breast cancer patients undergoing chemotherapy
    Madic, Jordan
    Kiialainen, Anna
    Bidard, Francois-Clement
    Birzele, Fabian
    Ramey, Guillemette
    Vinolo, Emilie
    Leroy, Quentin
    Rio-Frio, Thomas
    Bernard, Virginia
    Lermine, Alban
    Clausen, Inga
    Giroud, Nicolas
    Schmucki, Roland
    Horn, Carsten
    Spleiss, Olivia
    Lantz, Olivier
    Stern, Marc-Henri
    Pierga, Jean-Yves
    Weisser, Martin
    Lebofsky, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Circulating tumor cells in non-metastatic triple-negative breast cancer
    Mandar Karhade
    Carolyn Hall
    Priyankana Mishra
    Amber Anderson
    Henry Kuerer
    Isabelle Bedrosian
    Savitri Krishnamurthy
    Anthony Lucci
    Breast Cancer Research and Treatment, 2014, 147 : 325 - 333
  • [7] Circulating tumor cells in non-metastatic triple-negative breast cancer
    Karhade, Mandar
    Hall, Carolyn
    Mishra, Priyankana
    Anderson, Amber
    Kuerer, Henry
    Bedrosian, Isabelle
    Krishnamurthy, Savitri
    Lucci, Anthony
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 325 - 333
  • [8] Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).
    Duda, Dan G.
    Ziehr, David R.
    Guo, Hao
    Ng, Mei
    Barry, William Thomas
    Higgins, Michaela Jane
    Isakoff, Steven J.
    Brock, Jane E.
    Ivanova, Elena
    Paweletz, Cloud
    Demeo, Michelle
    Ramaiya, Nikhil H.
    Overmoyer, Beth
    Jain, Rakesh K.
    Winer, Eric P.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China
    Zhang, Yanwu
    Lv, Yidong
    Niu, Yaodong
    Su, Hongge
    Feng, Aiqiang
    MEDICAL SCIENCE MONITOR, 2017, 23 : 3071 - 3079
  • [10] Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer
    Liu, Zundong
    Ding, Mingji
    Qiu, Pengjun
    Pan, Kelun
    Guo, Qiaonan
    FRONTIERS IN IMMUNOLOGY, 2023, 14